Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia

Leukemia

Volumn 6, Issue 11, 1992, Pages 1189-1191

  Feldman, E ^a   Arlin, Z ^a   Ahmed, T ^a   Mittelman, A ^a   Puccio, C ^a   Chun, H ^a   Cook, P ^a   Baskind, P ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; HOMOHARRINGTONINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; DIARRHEA; DRUG RESPONSE; DRUG SAFETY; FEMALE; FLUID RETENTION; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; MALE; MUCOSA INFLAMMATION; NAUSEA; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HARRINGTONINES; HUMAN; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGE; RECURRENCE;

EID: 0026499681     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Warrell RP Jr, Coonley CJ, Gee TS. Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia. J Clin Oncol 1985; 3:617-621.
2. Arlin Z, Feldman E, Biguzzi S, et al. Phase I-II trial of Homoharringtonine (HHT) in acute leukemia. Proc Am Soc Clin Oncol 1987;6:628.
3. Okano T, Ohnuma T, Holland JF, Koeffler HP, Jui H. Effects of harringtonine in combination with acivicin, adriamycin, L-asparaginase, cytosine arabinoside, dexamethasone fluorouracil or methotrexate on human acute myelogenous leukemia cell line KG-1. Invest New Drugs 1983;1(2):145-150.
4. Warrell RP Jr, Berman E. Etoposide (VP-16) does not increase remission induction with homoharringtonine (HHT) in patients with acute non-lymphoblastic leukemia (ANLL). Proc Am Assoc Cancer Res 1986;27:192 (abstr).
5. Haines IE, Lowenthal DA, Warrell RP, Berman E, Kempin SJ. Homoharringtonine and amsacrine in pretreated patients with acute non-lymphocytic leukemia. Proc Am Soc Clin Oncol 1987;6:642.
6. Hematology Research Division and Hematology Section of the Children's Hospital, Suzhow Medical College, Suzhow. High remission induction (traditional Sino-Western HOAP) regimen for acute nonlymphocytic leukemia. Chin Med J 1980;93:565-568.
7. Miller AB, Hoogstraton B, Staquert M, Winkler A. Reporting results of cancer therapy. Cancer 1981;47: 207-214.
8. Kantarjian HM, Keating MJ, Walters RS, Koller CA, McCredie KB, Freireich EJ. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer 1989;63(5):813-817.
9. Stewart JA, Cassileth PA, Bennett JM, O'Connell MJ. Continuous infusion homoharringtonine in refractory acute nonlymphocytic leukemia. An ECOG pilot study. Am J Clin Oncol 1988;11(6):627-629.
10. Legha SS, Keating M, Picket S, Ajani JA, Ewer M, Bodey GP. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep 1984;68:1085-1091.
11. Cephalotaxus Research Coordinating Group. Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment. Chin Med 1976;2:263-272.
12. Feldman EJ, Arlin ZA, Ahmed T et al. Acute promyelocytic leukemia: a 5-year experience with new antileukemic agents and a new approach to preventing fatal hemorrhage. Acta Haematol 1989;82:117-121.
13. Jing-Song Y, Xiao-Hong W, Guang-Hui F, Gui-Ren L, Zhi-Ping L. Small dose harringtonine induces complete remission in patients with acute promyelocytic leukemia. Leukemia 1988;2:427-429.
14. Huang ME, Ye H-C, Chai JR, Lu HX, Zhoa L, Gu L-J, Wang Z-Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567.
15. Boyd AW, Sullivan JR. Leukemic cell differentiation in vivo an in vitro: Arrest of proliferation parallels the differentiation induced by the antileukemic drug harringtonine. Blood 1984;63:384-392.